8-K: STAAR Surgical Amends Alcon Merger, Launches Go-Shop Period

STAAR Surgical Company has amended its merger agreement with Alcon, introducing a 30-day go-shop period and waiving termination fees for superior offers from qualified bidders.

Summary

• STAAR Surgical Company entered into Amendment No. 1 to its Agreement and Plan of Merger with Alcon Research, LLC and Rascasse Merger Sub, Inc. on November 7, 2025.
• A 30-day 'go-shop' period has been established from November 7, 2025, until 11:59 p.m. (Eastern Time) on December 6, 2025, allowing STAAR to actively solicit and negotiate alternative acquisition proposals.
• During the go-shop period, STAAR is not required to notify Alcon of any proposals received.
• After the go-shop period, non-solicitation restrictions will apply, but STAAR may continue discussions with 'Qualified Bidders' who submitted a proposal during the go-shop period that could reasonably lead to a Superior Offer.
• The Termination Fee payable by STAAR to Alcon will be $0 if STAAR terminates the agreement to accept a Superior Offer from a Qualified Bidder, or if Alcon terminates due to a Company Adverse Recommendation Change related to a Superior Offer from a Qualified Bidder.
• Alcon has waived its right to match a Superior Offer from a Qualified Bidder.
• The special meeting of stockholders to vote on the merger, previously postponed to December 3, 2025, has been further postponed to December 19, 2025, at 8:30 a.m. Pacific Time.
• The record date for the special meeting remains October 24, 2025.

Sentiment

Score: 8

Explanation: The amendment significantly improves the terms for STAAR shareholders by allowing active solicitation of superior offers without a termination fee penalty and removing Alcon's matching rights, indicating a strong commitment to maximizing shareholder value. While there's a delay in the shareholder vote, the strategic flexibility gained is a net positive for potential value creation.

Positives

• A 30-day 'go-shop' period allows STAAR to proactively solicit higher bids, potentially maximizing shareholder value.
• No termination fee ($0) is payable to Alcon if STAAR accepts a superior offer from a qualified bidder, significantly reducing the cost of pursuing a better deal.
• Alcon has waived all matching rights for third-party proposals, removing a potential hurdle for competing bids.
• Limited information rights for Alcon during the go-shop period (STAAR is not required to notify Alcon of bids), fostering a more open process.
• Alcon has committed to engaging with STAAR stockholders and proxy advisory firms to understand their perspectives on valuation and other aspects of the merger proposal.

Negatives

• The further postponement of the Special Meeting of Stockholders to December 19, 2025, introduces additional delay and uncertainty regarding the merger's completion.
• The existence of a go-shop period implies that the initial Alcon offer might not have been considered optimal by some stakeholders or the board, potentially signaling dissatisfaction with the original terms.
• There is a risk that no superior offer emerges during the go-shop period, leading to continued uncertainty and potential stock price volatility.

Risks

• The occurrence of any event, change, or circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur.
• The failure to obtain approval of the proposed transaction from STAAR's stockholders.
• The failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all.
• Risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers, and others with whom it does business, or on its operating results and business generally.
• The ability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The possibility that no alternative proposals will be received during the go-shop period, or that any such alternative proposals are not determined by the STAAR board to be superior to the Alcon merger.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

The go-shop period is designed to explore potentially superior offers, indicating a forward-looking strategy to maximize shareholder value. The company anticipates continued dialogue with stockholders and Alcon's engagement with proxy advisory firms to understand their perspectives on valuation and other aspects of the merger proposal.

Management Comments

• "The STAAR Board continues to be committed to maximizing stockholder value." Stephen Farrell, CEO of STAAR.
• "This go-shop has provisions that encourage all potential buyers to come forward to provide their updated perspectives on valuation based on our most recent financial results and business trends." Stephen Farrell, CEO of STAAR.
• "This go-shop process will either produce a superior proposal or it will validate the merits of our proposed merger with Alcon. Either way, STAAR stockholders win." Stephen Farrell, CEO of STAAR.
• "We look forward to continuing our dialogue with our stockholders during this period." Stephen Farrell, CEO of STAAR.
• "In addition, we are pleased that Alcon has committed to begin engaging with STAAR stockholders and proxy advisory firms to understand their perspectives on valuation and other aspects of the Alcon merger proposal." Stephen Farrell, CEO of STAAR.

Industry Context

The ophthalmic surgery industry, particularly the phakic IOL segment where STAAR is a global leader, is subject to consolidation and strategic partnerships. This amendment suggests a competitive M&A environment where companies like STAAR seek to ensure optimal value for their innovative technologies, such as the EVO ICL. The involvement of a major player like Alcon highlights the strategic importance of STAAR's market position and the potential for further industry consolidation.

Corporate Governance

Legal Proceedings

• The filing mentions the 'outcome of any legal proceedings that may be instituted against the Company related to the proposed transaction' as a forward-looking risk, but does not detail any specific new or ongoing legal proceedings.

Stakeholder Impact

• Shareholders: Potential for increased acquisition value due to the go-shop period and reduced risk of a lower offer being accepted due to termination fees or matching rights. However, also introduces continued uncertainty until the go-shop period concludes and the shareholder vote occurs.
• Management/Employees: Potential disruption and distraction from ongoing business operations due to the proposed transaction and the go-shop process.
• Customers/Suppliers: Potential impact on relationships if the transaction creates uncertainty about the company's future.
• Alcon: Faces increased competition for the acquisition and has conceded significant terms (go-shop, no termination fee, no matching rights), indicating a strong desire to complete the merger despite these concessions.

Next Steps

• STAAR Surgical Company will actively solicit third-party acquisition proposals during the go-shop period, which ends on December 6, 2025.
• STAAR and its financial advisor plan to contact parties to invite interest in an alternative transaction to the Alcon merger.
• Alcon has committed to begin engaging with STAAR stockholders and proxy advisory firms to understand their perspectives on valuation and other aspects of the Alcon merger proposal.
• The Special Meeting of Stockholders to vote on the Alcon merger proposal is scheduled for December 19, 2025.
• STAAR will provide a new notice of the Special Meeting to stockholders of record as of October 24, 2025.

Key Dates

Recommendation

The introduction of a go-shop period, waiver of termination fees for superior offers, and Alcon's relinquishment of matching rights create an opportunity for a potentially higher bid for STAAR Surgical. This makes the current Alcon offer less definitive and introduces upside potential. However, the outcome of the go-shop is uncertain, and there's a risk that no superior offer materializes, or the merger could still fail. Therefore, holding the stock to observe the go-shop process and potential new bids is prudent, rather than buying into the current Alcon offer or selling prematurely before the full value exploration.

Keywords

STAAR Surgical, Alcon, Merger Agreement, Go-Shop Period, Acquisition Proposal, Superior Offer, Termination Fee, Stockholder Meeting, Ophthalmic Surgery, Implantable Collamer Lenses, EVO ICL, Vision Correction